Does SH2B3 rs3184504 alter blood-cell traits and hematopoietic signaling?

The SH2B3 gene encodes LNK, an intracellular adaptor protein that serves as a critical negative regulator of cytokine receptor signaling in hematopoietic stem and progenitor cells.

Mechanistic pathways

• The rs3184504 (p.R262W) variant is a well-characterized missense single nucleotide polymorphism that acts as a hypomorphic allele, resulting in a protein with reduced LNK function.
• Under normal physiological conditions, LNK binds to JAK2 and cytokine receptors—such as the erythropoietin receptor (EpoR) and the thrombopoietin receptor (MPL)—to attenuate downstream JAK-STAT signaling.
• The reduction in LNK function associated with the rs3184504 variant weakens this regulatory brake, leading to enhanced, hyper-responsive JAK2-dependent and JAK-STAT signaling in response to hematopoietic cytokines.

Blood-cell traits and clinical implications

• Multiple genome-wide association studies (GWAS) robustly demonstrate that the rs3184504 variant is associated with altered hematological profiles, including elevated platelet counts (driven by enhanced megakaryopoiesis), higher white blood cell and eosinophil counts, and elevated red blood cell parameters, such as hemoglobin and hematocrit.
• Beyond driving baseline blood-cell trait fluctuations, the altered signaling environment created by this hypomorphic allele acts as a genetic modifier that increases susceptibility to myeloproliferative neoplasms, particularly JAK2 V617F-positive polycythemia vera.

Bottom line

• The SH2B3 rs3184504 (R262W) variant is a functional hypomorphic allele that reduces LNK-mediated inhibition of JAK2 and MPL signaling, resulting in elevated red blood cell, white blood cell, and platelet counts, while increasing genetic susceptibility to myeloproliferative neoplasms.